Your search
Results 26 resources
-
<h2>Summary</h2><h3>Background</h3><p>Mucormycosis is an uncommon invasive fungal disease with high mortality and few treatment options. Isavuconazole is a triazole active in vitro and in animal models against moulds of the order Mucorales. We assessed the efficacy and safety of isavuconazole for treatment of mucormycosis and compared its efficacy with amphotericin B in a matched case-control analysis.</p><h3>Methods</h3><p>In a single-arm open-label trial (VITAL study), adult patients (≥18...
-
Background. Human metapneumovirus (hMPV) epidemiology, clinical characteristics and risk factors for poor outcome after allogeneic stem cell transplantation (allo-HCT) remain a poorly investigated area. Methods. This retrospective multicenter cohort study examined the epidemiology, clinical characteristics, and risk factors for poor outcomes associated with human metapneumovirus (hMPV) infections in recipients of allo-HCT. Results. We included 428 allo-HCT recipients who developed 438 hMPV...
-
Abstract Background Nocardiosis is rare after hematopoietic cell transplantation (HCT). Little is known regarding its presentation, management, and outcome in this population. Methods This retrospective international study reviewed nocardiosis episodes in HCT recipients (1/1/2000–31/12/2018; 135 transplant centers; 33 countries) and described their clinical, microbiological, radiological,...
-
AbstractObjectives. To define guidelines for BK polyomavirus (BKPyV)-associated haemorrhagic cystitis (BKPyV-HC) after paediatric and adult HSCT.Methods. Revi
-
Background. Neutropenia may limit use of valganciclovir treatment for cytomegalovirus (CMV) infection following hematopoietic cell transplant (HCT). A phase 2 study indicated efficacy of maribavir with fewer treatment-limiting toxicities than valganciclovir. Methods. In this multicenter, double-blind, phase 3 study, patients with first asymptomatic CMV infection post-HCT were stratified and randomized 1:1 to maribavir 400 mg twice daily or valganciclovir (dose-adjusted for renal clearance)...
-
Invasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ...
Filter by our tag
GUIDELINES
- ECIL Guidelines (6)
- ESCMID Guidelines (1)
TEXTBOOKS
ORGANISMS
-
BACTERIA
(2)
- Nocardia (1)
- Non-tuberculous Mycobacteria (1)
- Tuberculosis (1)
-
FUNGI
(7)
- Aspergillus (3)
- Mucormycosis (2)
- Pneumocystis (2)
-
PARASITES AND PROTOZOA
(1)
- Toxoplasmosis (1)
-
VIRUSES
(8)
- Adenovirus (1)
-
CMV
(4)
- Letermovir (1)
- Maribavir (3)
-
COVID-19
(1)
- Treatments (1)
- Polyomaviruses (1)
- Respiratory Viruses (1)
DIAGNOSTICS
DRUGS AND THERAPIES
- Antifungals (5)
HEME-ONC AND CELLULAR THERAPIES
- Biologics (1)
- BMT Guidelines (1)
- BMT-specific ID (4)
- Heme-onc prophylaxis (1)
- Neutropenia (1)
- PEDIATRIC (1)
- TK inhibitors (1)
ATC 2023 Top Papers in TID
- FUNGI (1)
ATC 2024 Top Papers in TID
- VIRUSES (1)